

<b>Form PTO-1449</b> U.S. Department of Commerce Patent & Trademark Office  <b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>		Atty. Docket No. 147/50194	Serial No. TBA
		Applicant Regina SCOEMAKEX	
		Filing Date August 1, 2001	Group

147/50194 U.S. PTO  
 09/01/01  
 07/31/01

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
	AA						

FOREIGN PATENT DOCUMENTS							
		Document	Date	Country	Class	Sub-class	Translation Yes   No
↓	AB	EP0317855	08/1990	Europe			Abstract
↓	AC	WO9746241	12/1997	WO			Yes

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
↓	AD	Rene Roland WENZEL, "I <sub>1</sub> -Imidazoline Agonist Moxonidine Decrease Sympathetic Nerve Activity and Blood Pressure in Hypertensives" Hypertension, December 1998
↓	AE	W. LADA, "Imidazoline-prefering receptors and the I <sub>1</sub> -imidazoline blocking therapy" Pol. Merk. Lek., 1996
↓	AF	Istvan LEPRAN, "Effect of Moxonidine on Arrhythmias Induced by Coronary Artery Occlusion and Reperfusion" Journal of Cardiovascular Pharmacology, 1994
↓	AG	W. LADA, "Imidazoline-prefering receptors and the I <sub>1</sub> -imidazoline blocking therapy" Pol. Merk. Lek., 1996

EXAMINER <i>L. Channavajjala</i>	DATE CONSIDERED <i>4-2-02</i>
----------------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.